3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Metabolism, Inborn Errors
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Immunoblastic Lymphadenopathy
1
Hemoglobinopathies
1
Graft vs Host Disease
1
Congenital Bone Marrow Failure Syndromes
1
Bone Marrow Failure Disorders
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Pemetrexed
22
Cisplatin
20
Nivolumab
8
Gemcitabine
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
Bevacizumab
5
pembrolizumab
4
Radiotherapy, Intensity-Modulated
4
tremelimumab
3
niraparib
3
Oxaliplatin
3
Drug Therapy
3
Cyclophosphamide
3
Cerebral Decortication
3
Blood Specimen Collection
3
sargramostim
2
Thoracoscopy
2
Surveys and Questionnaires
2
Sorafenib
2
Radiosurgery
2
Magnesium Sulfate
2
Leucovorin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Dexamethasone
2
tislelizumab
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma
×
Clinical Trials, Phase I as Topic
×
Clear all
NCT03655834
2022-05-10
IMPROVE-III
Radboud University Medical Center
Phase 4
Completed
10 enrolled